Drug Topics - October 29, 2007 - (Page 4)

4 DRUG TOPICS OCTOBER 29, 2007 www.drugtopics.com Of Interest to Pharmacists N.J. R.Ph.s urge action against Medicaid generic reimbursement rule Lawrence D. Tobias ew Jersey pharmacists gathered recently to draw attention to and protest against what they hold to be a flawed program for Medicaid generic prescription drug reimbursement as contained in the Deficit Reduction Act (DRA) of 2005. The group also came out in support of pending legislation—H.R. 3140, the Saving Our Community Pharmacies Act of 2007—from Rep. Frank Pallone (D, N.J.), chairman of the House Energy & Commerce Committee’s Subcommittee on Health, which they claim is critically needed to offset the negative fallout of the new rule for N.J. pharmacists gathered to independent pharmacies. protest the generic reimburseJohn Covello, executive director of ment levels of the Deficit Regovernment and public affairs, Indeduction Act of 2005. pendent Pharmacy Alliance (IPA), a trade group that represents 650 N.J. independent pharmacies, chaired the event, held at Zajac’s Pharmacy in New Brunswick, N.J., last month. He was assisted by Stephen Brandt, executive director of the Garden State Pharmacy Owners (GSPO), and Pete Reiss, executive VP of GSPO. N ello indicated that, given the greater size and scale of chain pharmacies relative to independents, it is not surprising that “AMP is not an accurate reflection of actual retail acquisition cost, because it includes many sales prices that are not available to independent pharmacies like the one we are gathered at today, Zajac’s Pharmacy, in the formula.” Mike Fedida, R.Ph., owner of J&J Pharmacy in Teaneck, N.J., agreed, adding, “No one has clearly defined what the reimbursement will be. We understand the following from reading the literature and from some of the organizations that support us—we are going to be paid 36% less on average on the cost of generic drugs.” Reason for hope H.R. 3140 is designed to address the shortcomings readily apparent with reimbursement for generics based upon AMP and would define the benchmark for pharmacy re, imbursement to accurately reflect true community pharmacy acquisition costs, by avoiding those price concessions and rebates provided to chain drugstores, but unavailable to community pharmacies. Covello urged Pallone to ensure that his subcommittee votes on H.R. 3140 and afterwards reconciles in committee any differences in a similar bill pending in the Senate, S. 1951, the Fair Medicaid Drug Payment Act of 2007. Another possible offset to reimbursement shortfalls under AMP involves increasing dispensing fees for generics, which have remained at $3.65 for Medicaid Rxs, essentially unchanged since the early 1980s. Brandt cited studies that indicate current dispensing fees for generic drugs are in the range of $10 per Rx. He said that CMS has the final say in approving increases in dispensing fees for Medicaid drugs and recently rejected an increase in Louisiana. “Every one of us is only one catastrophic illness or major accident away from the safety net that Medicaid provides for us. The true measure of a great society is how we treat our elderly, our young, and our infirm,” said Tom Kelly, R.Ph., owner of Medicine To Go in Forked River and Lakewood. “If we cast aside support for providing care for these patient populations at home and in their community, we are really letting down these patient populations, and, in effect, tearing holes in the safety net that provides pharmaceutical services for the Medicaid population.” THE AUTHOR Opting out “The Centers for Medicare & Medicaid Services has created a reimbursement system [based on AMP—average manufacturer price—in place of AWP—average wholesale price] that will cause many independent pharmacies in New Jersey and across the country to either limit or drop their participation in Medicaid,” said Covello. “If a pharmacy has a high percentage of Medicaid patients, it might even go out of business. All of this is happening not because of free market competition but because of misguided government policy.” He added that “the real effect of AMP is that it could threaten to stamp out independent pharmacies in urban and community environments all across the nation.” AMP is anything but simple to calculate. It ideally should take into account the following: bundled offerings, value-added offerings, selective discounts, rebates, and other price incentives. Taken together, these price incentives commoditize the issue of generic pricing by obscuring true line-item pricing and true acquisition cost. Cov- is a writer based in New Jersey. Photo: Lawrence D. Tobias http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - October 29, 2007

Drug Topics - October 29, 2007 Contents N.J. R.Ph.s Take AMP Fight to Congress Oral Care Product Sales Holding Steady Still More Stellar Independent Pharmacies Students to Students: Check Out Our Book The Week at a Glance

Drug Topics - October 29, 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.